SureGene and PGXL Laboratories announced the launch of SureGene Test for Antipsychotic and Antidepressant Response (STA2R), a pharmacogenetic test containing genetic markers for effectiveness of antipsychotic drug treatment. STA2R provides clinicians with necessary information in clinical response, adverse event liability, and drug metabolism to facilitate personalized antipsychotic and antidepressant drug selection.
STA2R combines the propriety SULT4A1-1 genetic signature with four other gene tests. Clinical studies in Caucasian schizophrenic patients have indicated that SULT4A1-1 positive patients treated with olanzapine (Zyprexa; Lilly) have greater reduction in psychotic symptoms and a significantly lower risk of being hospitalized. Additionally, STA2R helps identify those patients for whom risperidone (Risperdal; Janssen), the current standard treatment, is contraindicated and specific patients that may not respond as well to certain antidepressants. STA2R’s collection process requires a simple cheek swab in a healthcare professional’s office, where it is shipped to PGXL Laboratories. Within a few days, the clinician receives a secure report.
SureGene discovered and patented the SULT4A1 genetic signature. PGXL Laboratories independently developed the STA2R test and will exclusively perform the test in its laboratory.
For more information call (502) 569-1584 or visit www.suregenetest.com.